Table 4 Relationship between of IL1A expression and clinical characteristics of patients with CESC
Gene | Characteristics | Total (N) | Odds ratio (OR) | P value |
|---|---|---|---|---|
IL1A | Age (≤ 50 vs. > 50) | 304 | 1.153 (1.029–1.298) | 0.016 |
BMI (≤ 25 vs. > 25) | 259 | 1.076 (0.953–1.215) | 0.238 | |
Menopause status (Pre vs. Peri and Post) | 231 | 1.182 (1.040–1.351) | 0.012 | |
Histological type (adenosquamous vs. squamous cell carcinoma) | 304 | 0.234 (0.140–0.357) |  < 0.001 | |
T stage (T1 and T2 vs. T3 and T4) | 241 | 0.877 (0.738–1.047) | 0.138 | |
N stage (N0 vs. N1) | 193 | 0.997 (0.861–1.158) | 0.963 | |
M stage (M0 vs. M1) | 126 | 1.004 (0.743–1.419) | 0.980 | |
Clinical stage (Stage I and stage II vs. stage IV and stage III) | 297 | 0.893 (0.787–1.015) | 0.080 | |
Histologic grade (G1 and G2 vs. G4 and G3) | 272 | 1.088 (0.967–1.227) | 0.164 | |
Primary therapy outcome (SD and PR and CR vs. PD) | 217 | 0.819 (0.675–0.995) | 0.042 | |
Radiation therapy (yes vs. no) | 304 | 0.988 (0.886–1.103) | 0.827 |